Panamor AT-50 9s

Panamor AT-50 9s, an antimalarial combination therapy:

Panamor AT-50 9s - Complete Antimalarial Profile

📌 Therapeutic Class:
Artemisinin-based Combination Therapy (ACT)

✅ Active Ingredients (per blister pack):

• Artesunate (50mg) – Fast-acting schizonticide

• Amodiaquine (153mg base) – Long-acting blood schizonticide

🎯 Primary Indications:
✔️ Acute uncomplicated Plasmodium falciparum malaria
✔️ First-line treatment in malaria-endemic regions
✔️ Pediatric malaria (weight-based dosing)

Dosage & Administration

Standard 3-Day Regimen (Adults & Children >10kg):

• Day 1: 4 tablets (single dose)

• Day 2: 2 tablets

• Day 3: 2 tablets

• Total: 8 tablets per treatment course

Weight-Based Pediatric Dosing:

⚠️ Critical Contraindications:

• 1st trimester pregnancy

• Severe malaria (requires parenteral artesunate)

• Amodiaquine hypersensitivity

• Liver dysfunction (Child-Pugh B/C)

Key Clinical Considerations

⚡ Mechanism:

• Artesunate: Rapid parasite clearance (↓ 90% parasite biomass in 12h)

• Amodiaquine: Eliminates residual parasites

💊 Drug Interactions:

• ↑ QT prolongation with macrolides/antipsychotics

• ↓ Efficacy with strong CYP2C8 inducers

• ↑ Hepatotoxicity risk with rifampin

📉 Adverse Effects:

• Common: Nausea, dizziness, transient neutropenia

• Serious: Hepatotoxicity, agranulocytosis (rare)

Patient Counseling

🔹 Take with fatty food (enhances amodiaquine absorption)
🔹 Complete full course (even if symptoms resolve)
🔹 Report immediately: Dark urine, jaundice, or fever recurrence

🛑 Discontinue if:

• Signs of hypersensitivity (rash, angioedema)

• Persistent vomiting (<1h post-dose requires repeat dose)